Quantification of receptors for estradiol-17 beta and progesterone in the pituitary and hypothalamus of prepubertal gilts induced to ovulate with pregnant mare's serum and human chorionic gonadotropin.
Nuclear and cytoplasmic exchange assays were developed and validated to quantify receptors for estradiol-17 beta (E217 beta) and progesterone (P4) in hypothalamic and pituitary tissues of gilts before, during, and after treatment with pregnant mare's serum (PMS) and human chorionic gonadotropin (hCG). Prepubertal gilts, 5 months old, were assigned randomly to four treatments. One group of gilts received 500 IU PMS (Day 0) and were sacrificed 2 days later (2 days post-PMS); another group received 500 IU PMS on Days 0 and 2, and were sacrificed 4 days from the initial injection (4 days post-PMS). A third group of gilts received PMS (500 IU) on Days 0 and 2, 1000 IU hCG on Day 4, and were sacrificed 5 days after hCG (5 days post-hCG). Controls were given saline on Days 0, 2 and 4 and sacrificed on Day 6. In pituitary tissues, there were no significant changes in numbers of cytoplasmic E2 17 beta receptors, cytoplasmic P4 receptors, nuclear P4 receptors or nuclear E2 17 beta receptors among the control, 2 days post-PMS, 4 days post-PMS or 5 days post-hCG treatment groups. In hypothalamic tissues, no differences in cytoplasmic E2 17 beta receptors, cytoplasmic P4 receptors or nuclear P4 receptors were found among any of the treatments. Nuclear receptors for E2 17 beta in hypothalamic tissues were greater, however, in gilts 2 days post-PMS (P less than 0.05) than in controls or 5 days post-hCG gilts, but they were not different from gilts 4 days post-PMS. Follicular development and serum concentrations of E2 17 beta followed the expected patterns after PMS; only ovaries from hCG-treated pigs contained corpora lutea. Because the PMS-hCG regimen simulated the onset of puberty, it seems that gilts attain puberty without a significant change in the number of receptors for E2 17 beta and P4 in the pituitary or hypothalamus.
D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D004971:Estrus; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D007031:Hypothalamus / Q000378:metabolism*; D010053:Ovary / Q000187:drug effects; D010062:Ovulation Induction / Q000662:veterinary*; D010902:Pituitary Gland / Q000378:metabolism*; D011247:Pregnancy; D011959:Receptors, Estradiol; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012741:Sexual Maturation / Q000187:drug effects; D013552:Swine / Q000502:physiology*
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D011959:Receptors, Estradiol; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone